CRISPR Therapeutics AG (CRSP) Market Cap & Valuation Ratios
CRISPR Therapeutics AG (CRSP) has a market cap of $4.8B and a price-to-sales ratio of 356.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRSPCRISPR Therapeutics AGFollow CRSP — free
—
Price chart with a free account
- Market cap
- 4.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| CRSP | 4.8 | — | 223.8 | — | -7.8% | -65% | — | -30% |
| ORKA | 5.3 | — | — | — | -1.9% | — | — | -28% |
| MIRM | 5.2 | — | 8.9 | — | -4.4% | +44% | -135% | -224% |
| PTCT | 5.1 | — | 3.4 | 18.9 | -0.8% | -43% | 12% | — |
| SRRK | 5.1 | — | — | — | -5.9% | — | — | -568% |
| ERAS | 5.0 | — | — | — | -1.9% | — | — | -97% |
| DFTX | 4.8 | — | — | — | -3.5% | — | — | -92% |
| TVTX | 4.7 | — | 8.5 | 219.5 | 2.0% | +77% | -7% | -8% |
| GOSS | 4.6 | — | 86.3 | — | -3.5% | +32% | -312% | — |
| DNTH | 4.3 | — | — | — | -3.6% | -61% | — | -32% |
| EWTX | 4.3 | — | — | — | -3.7% | — | — | -48% |
| Median of these 10 | — | 8.7 | 119.2 | -3.5% | +32% | -71% | -70% |
; EV/Sales 223.8 vs. 8.7.
Growth vs. price
each dot a company · hover or tap for valuesCRISPR Therapeutics AG — questions
- What is CRISPR Therapeutics AG's market cap?
- $4.8B.
- What is CRISPR Therapeutics AG's price-to-sales ratio?
- 356.6.
Every figure on this page comes from CRISPR Therapeutics AG's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.